As the World Health Organization's Framework Convention on Tobacco Control (WHO FCTC) gears up for its 11th Conference of the Parties (COP11) in Geneva from November 15 to 22, 2025, the global tobacco control landscape is facing a major standoff. At the heart of the debate is whether vapes and other novel nicotine products should be embraced as harm reduction tools. This tension highlights deep divisions within the EU and on the international stage, where public health goals clash with financial interests and industry pressures, making any path to agreement feel like navigating a minefield.
The Uneven Progress in Global Tobacco Control
The COP11 agenda promises heated discussions on several fronts, including harmonizing taxes on nicotine products worldwide, advancing protocols against illicit trade, and crafting regulations for emerging products like vapes, nicotine pouches, and heated tobacco devices.
The WHO is poised to push for tougher restrictions, citing a sharp rise in teen vaping as a red flag. On the flip side, industry groups and harm reduction advocates argue that overly rigid rules could backfire, failing to curb demand and potentially driving users back to more dangerous traditional cigarettes.
In the EU, tobacco-related diseases remain the leading cause of preventable deaths, claiming up to 700,000 lives prematurely each year. Recent WHO data shows adult smoking rates hovering between 23% and 25% across the bloc, but the picture varies wildly by country—from Sweden, where harm reduction alternatives have helped drop rates below 10%, to some Eastern European and Balkan nations where smoking stubbornly exceeds 35%.
Clashing Philosophies: Harm Reduction vs. Total Abstinence
COP11 will spotlight a philosophical showdown in public health. One camp, led by countries like the UK and Sweden, champions harm reduction. Their view? For adults who can't or won't quit nicotine entirely, policies should guide them toward less harmful options backed by science, away from combustible cigarettes.
Sweden stands out as a prime example. By normalizing and regulating smoke-free alternatives like oral nicotine pouches, the country has slashed its smoking rate to under 5%—the lowest in Europe—and seen cancer rates fall well below the continental average.
Opposing them is a more cautious faction, anchored by the WHO and echoed by several EU members. They eye any product promoted by the tobacco industry with deep suspicion, warning of unknown long-term risks and the bigger danger: these items might "renormalize" nicotine use, undoing decades of hard-won anti-smoking progress.
This core clash is set to peak in debates over Article 5.3 of the FCTC, which aims to shield public health policymaking from tobacco industry influence. WHO's briefing papers for COP11 stress this threat, urging maximum vigilance to prevent structural conflicts between health policies and commercial agendas.
Economic Realities: Taxes, Black Markets, and Tough Choices
Beyond health concerns, policymakers grapple with gritty economics. Tobacco products are a cash cow for governments, especially in the EU, where excise taxes rake in over €80 billion annually.
The ongoing revision of the Tobacco Excise Directive (TED) seeks to fold novel nicotine products into a solid tax framework. Proponents of stricter rules say a unified minimum tax rate at the EU level could plug loopholes from varying national systems and stop policy arbitrage.
But critics caution that heavy-handed tax harmonization might disproportionately burden smaller economies and inadvertently fuel black markets, worsening the already rampant illicit trade.
It's a classic bind: how to wield deterrent pricing without sparking more cross-border smuggling and underground dealings, especially in a union with stark tax disparities.
EU's Internal Balancing Act: From Bold Ambitions to Political Compromises
The EU faces a unique hurdle at COP11—forging a single negotiating stance among 27 sovereign nations with wildly differing views on tobacco harm reduction.
A leaked draft of the EU's position revealed initial bold strokes, like banning cigarette filters for their environmental harm and misleading health perceptions, imposing blanket flavor bans on all tobacco products, and subjecting all new nicotine devices to stringent FCTC oversight.
Yet, Brussels' political grind quickly toned these down. Insiders say the outright filter ban morphed into vague talk of "phasing down environmental pollution from filters," while the flavor prohibition softened to "considering regulation where appropriate."
These shifts underscore the EU's economic and political sensitivities. Nations with robust manufacturing sectors resist outright bans, while harm reduction proponents, inspired by the UK, lobby for nuanced treatment of proven lower-risk products.
Effective smoking cessation tools:Vapepie 40000
Looking Ahead: Shaping the Future of Global Tobacco Control
For policymakers, scientists, and civil society worldwide, the Geneva gathering is a pivotal moment that could define the next decade of tobacco and nicotine policy. Will we stick to the absolutist "quit or nothing" approach, or pivot to a pragmatic strategy that incorporates harm reduction?
Europe's challenge is particularly acute: striking a balance between ironclad health protections and fostering lower-risk innovations, all grounded in independent science and transparent decision-making.
Meanwhile, big tobacco firms are rebranding themselves as pioneers of a "smoke-free future," pouring billions into alternative nicotine tech. They pitch these as better choices for adults, aligning with public health aims. But skeptics call it a smokescreen, hiding ongoing reliance on profitable cigarettes and using lobbying, PR, and selective research funding to stall real regulations.
How Brussels positions itself at COP11 and advances revisions to the Tobacco Products Directive (TPD) and TED will ripple through European laws for years. A strong, unified EU stance isn't just about this meeting—it's about steering the global tobacco control trajectory for the decade ahead.